adenomatous polyposis coli


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.
Related to adenomatous polyposis coli: Familial adenomatous polyposis

familial adenomatous polyposis (FAP),

[MIM*175100]
polyposis that usually begins in childhood; polyps increase in number, causing symptoms of chronic colitis; pigmented retinal lesions are frequently found; carcinoma of the colon almost invariably develops in untreated cases; autosomal dominant inheritance, caused by mutation in the adenomatous polyposis coli gene (APC) on 5q. In Gardner syndrome, which is allelic to FAP, there are extracolonic changes (desmoid tumors, osteomas, jaw cysts).

adenomatous polyposis coli (APC)

a gene associated with familial adenomatous polyposis (FAP), an inherited disorder characterized by the development of myriad polyps in the colon, often occurring in adolescents and young adults ages 15 to 25. Untreated, the condition nearly always leads to colon cancer. The gene is located on chromosome 5.
enlarge picture
Familial adenomatous polyposis

APC

Abbreviation for:
activated protein C (see there)
adenomatous polyposis coli (see there)
aerobic plate count  (microbiology)
air pollution control
allophycocyanin
ammonium perchlorate
amyloid pack core 
antigen-presenting cell (see there)
antiphlogistic-corticoid (obsolete)
aperature current
apneustic centre  (neuroanatomy)
arterial premature contraction
aspirin, phenacetin, caffeine
Association of Pathology Chairmen
Association of Professors of Cardiology
atrial premature contraction (see there)
Adenoma Prevention with Celecoxib (clinical trials)
ambulatory payment classification (see there) (Managed care)
APC gene (molecular medicine)
APC protein (molecular medicine)

Genetics
A gene on chromosome 5q21-q22 that encodes a tumour-suppressor protein which acts as an antagonist of the Wnt signalling pathway. APC is also involved in cell migration and adhesion, transcriptional activation, and apoptosis.

Molecular Pathology
APC mutations cause familial adenomatous polyposis.

adenomatous polyposis coli

Familial adenomatous polyposis, see there. See APC gene, APC protein.

fa·mi·li·al ad·e·nom·a·tous pol·y·po·sis

(FAP) (fă-mil'ē-ăl ad'ĕ-nō'mă-tŭs pol'i-pō'sis)
Polyposis of the colon that usually begins in childhood; polyps increase in number, causing symptoms of chronic colitis; pigmented retinal lesions are frequently found; carcinoma of the colon almost invariably develops in untreated cases; autosomal dominant inheritance, caused by mutation in the adenomatous polyposis coli gene (APC) on 5q. In Gardner syndrome, which is allelic to FAP, there are extracolonic changes (desmoid tumors, osteomas, jaw cysts).
Synonym(s): adenomatous polyposis coli, familial polyposis coli.
References in periodicals archive ?
A snapshot of the global therapeutic scenario for Familial Adenomatous Polyposis Coli.
A review of the Familial Adenomatous Polyposis Coli products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Prevalence of the Y165C, G382D, and 1395deIGGA germline mutations of the MYH gene in Italian patients with adenomatous polyposis coli and colorectal adenomas.
Mutations of APC and MYH in unrelated Italian patients with adenomatous polyposis coli.
Coverage of the Familial Adenomatous Polyposis Coli pipeline on the basis of therapeutic class, route of administration and molecule type.
1, 1999, the company announced that it anticipated a delay in commercialization of exisulind for Adenomatous Polyposis Coli (APC) because a preliminary evaluation suggested that data produced in its recently concluded Phase III study did not provide the overall statistical results which the study was designed to provide.
Nasdaq:CLPA) today announced that it anticipates a delay in the filing of its NDA for its novel investigational drug, PREVATAC(tm) (exisulind) for Adenomatous Polyposis Coli (APC), which was initially planned for March of this year.
The company's lead investigational drug, PREVATAC(tm)(exisulind) is currently completing a Phase III study for the prevention of the formation of precancerous colon polyps in patients with adenomatous polyposis coli (APC)(also known as familial adenomatous polyposis, or FAP).
That drug is currently completing a Phase III trial as a treatment for precancerous colon polyps in patients with adenomatous polyposis coli (APC), and is additionally under study for the prevention of prostate and breast cancer recurrence and as a treatment for sporadic precancerous colon polyps and lung cancer.
Cell Pathways is currently completing a Phase III trial with its lead compound, PREVATAC(tm) (exisulind), for the treatment of precancerous lesions in patients with adenomatous polyposis coli (APC), and expects to complete a New Drug Application filing for this indication in the first half of 1999.